000275935 001__ 275935
000275935 005__ 20250126000520.0
000275935 0247_ $$2doi$$a10.1007/s00259-024-06923-3
000275935 0247_ $$2pmid$$apmid:39352424
000275935 0247_ $$2ISSN$$a1619-7070
000275935 0247_ $$2ISSN$$a1619-7089
000275935 0247_ $$2altmetric$$aaltmetric:168969056
000275935 037__ $$aDZNE-2025-00157
000275935 041__ $$aEnglish
000275935 082__ $$a610
000275935 1001_ $$aLiu, Feng-Tao$$b0
000275935 245__ $$aVisual reading for [18F]Florzolotau Tau PET scans in progressive supranuclear palsy.
000275935 260__ $$aHeidelberg [u.a.]$$bSpringer-Verl.$$c2025
000275935 3367_ $$2DRIVER$$aarticle
000275935 3367_ $$2DataCite$$aOutput Types/Journal article
000275935 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1737366843_5000
000275935 3367_ $$2BibTeX$$aARTICLE
000275935 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000275935 3367_ $$00$$2EndNote$$aJournal Article
000275935 520__ $$aThe identification of tau accumulation within living brains holds significant potential in facilitating accurate diagnosis of progressive supranuclear palsy (PSP). While visual assessment is frequently employed, standardized methods for tau positron emission tomography (PET) specifically in PSP are absent. We aimed to develop a visual reading algorithm dedicated to the evaluation of [18F]Florzolotau PET in PSP.148 PSP and 30 healthy volunteers were divided into a development set (for the establishment of the reading rules; n = 89) and a testing set (for the validation of the reading rules; n = 89). For differential diagnosis, 55 α-synucleinopathies were additionally included into the testing set. The visual reading method was established by an experienced assessor (Reader 0) and was then validated by Reader 0 and two additional readers on regional and overall binary manners. A positive binding in both midbrain and globus pallidus/putamen regions was characterized as a PSP-like pattern, whereas any other pattern was classified as non-PSP-like.Reader 1 (94.4%) and Reader 2 (93.8%) showed excellent agreement for the overall binary determination against Reader 0. The regional binary determinations of midbrain and globus pallidus/putamen showed excellent agreement among readers (kappa > 0.80). The overall binary evaluation demonstrated reproducibility of 86.1%, 94.4% and 77.8% for three readers. The visual reading algorithm showed high agreement with regional standardized uptake value ratios and clinical diagnoses.Through the application of the suggested visual reading algorithm, [18F]Florzorotau PET imaging demonstrated a robust performance for the imaging diagnosis of PSP.
000275935 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x0
000275935 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000275935 650_7 $$2Other$$aPositron emission tomography
000275935 650_7 $$2Other$$aProgressive supranuclear palsy
000275935 650_7 $$2Other$$aVisual reading algorithm
000275935 650_7 $$2Other$$a[18F]Florzorotau
000275935 650_7 $$2NLM Chemicals$$atau Proteins
000275935 650_7 $$2NLM Chemicals$$aAniline Compounds
000275935 650_7 $$2NLM Chemicals$$aCarbolines
000275935 650_7 $$2NLM Chemicals$$aRadiopharmaceuticals
000275935 650_2 $$2MeSH$$aHumans
000275935 650_2 $$2MeSH$$aSupranuclear Palsy, Progressive: diagnostic imaging
000275935 650_2 $$2MeSH$$aSupranuclear Palsy, Progressive: metabolism
000275935 650_2 $$2MeSH$$aPositron-Emission Tomography: methods
000275935 650_2 $$2MeSH$$aMale
000275935 650_2 $$2MeSH$$aFemale
000275935 650_2 $$2MeSH$$atau Proteins: metabolism
000275935 650_2 $$2MeSH$$aAged
000275935 650_2 $$2MeSH$$aMiddle Aged
000275935 650_2 $$2MeSH$$aAniline Compounds
000275935 650_2 $$2MeSH$$aCase-Control Studies
000275935 650_2 $$2MeSH$$aCarbolines: pharmacokinetics
000275935 650_2 $$2MeSH$$aRadiopharmaceuticals: pharmacokinetics
000275935 650_2 $$2MeSH$$aAlgorithms
000275935 7001_ $$aLu, Jia-Ying$$b1
000275935 7001_ $$aLi, Xin-Yi$$b2
000275935 7001_ $$aGe, Jing-Jie$$b3
000275935 7001_ $$aSun, Yi-Min$$b4
000275935 7001_ $$aYen, Tzu-Chen$$b5
000275935 7001_ $$aJiao, Fang-Yang$$b6
000275935 7001_ $$aChen, Ming-Jia$$b7
000275935 7001_ $$aZhao, Jun$$b8
000275935 7001_ $$aYao, Rui-Xin$$b9
000275935 7001_ $$aTang, Gan$$b10
000275935 7001_ $$aXu, Hao$$b11
000275935 7001_ $$aLan, Xiao-Li$$b12
000275935 7001_ $$aLu, Jie$$b13
000275935 7001_ $$aCui, Rui-Xue$$b14
000275935 7001_ $$0P:(DE-2719)9001539$$aBrendel, Matthias$$b15$$udzne
000275935 7001_ $$aShi, Kuangyu$$b16
000275935 7001_ $$aGuan, Yi-Hui$$b17
000275935 7001_ $$aRominger, Axel$$b18
000275935 7001_ $$aWang, Jian$$b19
000275935 7001_ $$00000-0002-8856-7217$$aZuo, Chuan-Tao$$b20
000275935 7001_ $$aInitiative, Progressive Supranuclear Palsy Neuroimage$$b21$$eCollaboration Author
000275935 773__ $$0PERI:(DE-600)2098375-X$$a10.1007/s00259-024-06923-3$$gVol. 52, no. 2, p. 586 - 598$$n2$$p586 - 598$$tEuropean journal of nuclear medicine and molecular imaging$$v52$$x1619-7070$$y2025
000275935 8564_ $$uhttps://pub.dzne.de/record/275935/files/DZNE-2025-00157%20SUP.docx
000275935 8564_ $$uhttps://pub.dzne.de/record/275935/files/DZNE-2025-00157_Restricted.pdf
000275935 8564_ $$uhttps://pub.dzne.de/record/275935/files/DZNE-2025-00157_Restricted.pdf?subformat=pdfa$$xpdfa
000275935 8564_ $$uhttps://pub.dzne.de/record/275935/files/DZNE-2025-00157%20SUP.doc
000275935 8564_ $$uhttps://pub.dzne.de/record/275935/files/DZNE-2025-00157%20SUP.odt
000275935 8564_ $$uhttps://pub.dzne.de/record/275935/files/DZNE-2025-00157%20SUP.pdf
000275935 909CO $$ooai:pub.dzne.de:275935$$pVDB
000275935 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001539$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b15$$kDZNE
000275935 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x0
000275935 9141_ $$y2025
000275935 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2024-12-05$$wger
000275935 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2024-12-05$$wger
000275935 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J NUCL MED MOL I : 2022$$d2024-12-05
000275935 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-05
000275935 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-05
000275935 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-05
000275935 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-05
000275935 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-05
000275935 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-05
000275935 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-05
000275935 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-05
000275935 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-05
000275935 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-05
000275935 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR J NUCL MED MOL I : 2022$$d2024-12-05
000275935 9201_ $$0I:(DE-2719)1110007$$kAG Haass$$lMolecular Neurodegeneration$$x0
000275935 980__ $$ajournal
000275935 980__ $$aVDB
000275935 980__ $$aI:(DE-2719)1110007
000275935 980__ $$aUNRESTRICTED